Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)

Sponsor
Beijing Anzhen Hospital
Study ID
NCT04087915
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Evolocumab — DRUG
    Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference

Study Details

The primary objective was to evaluate the effect of treatment with evolocumab on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with high risk coronary artery disease.

Key Dates

Start date
Sep 11, 2019
Status verified
Dec 2020
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: High risk coronary artery disease
    Participants with high risk coronary artery disease.

Primary Outcome Measure

Occurrence of main adverse cardiovascular and cerebrovascular events (MACCE) [ Time Frame: 1 year ]

Central Contacts

Related Studies